In 2015, the Global Fund’s Technical Evaluation Reference Group (TERG) brought together two distinct strategy review components to independently assess the Global Fund’s work – a ten-year evaluation, including impact against the three diseases, and a mid-term appraisal of progress in the implementation of the Global Fund Strategy 2012-2016 – into a consolidated effort termed the ‘Strategic Review 2015’ (SR2015). Itad, in consortium with Euro Health Group and collaborating with the University of California, San Francisco, was contracted to undertake the SR 2015.
Itad was commissioned to conduct a Strategic Review 2017 (SR2017) as a follow on to the SR2015 that would assess progress specifically made during the final two years of the Global Fund Strategy 2012 – 2016, and analyse as to how lessons learned are contributing to the readiness of the Global Fund in implementing it’s 2017 – 2022 Strategy.
Throughout the assignment we employed a mixed methods approach using both qualitative and quantitative data collection and analysis. The SR2017 required the team to assess a large amount of existing secondary data, which was enhanced and complemented by semi-structured Key Informant Interviews at central and country level. Case studies in four countries were undertaken to collect more in-depth, primarily qualitative information to inform our analysis. The four case studies that were selected were Benin, Kenya, Moldova and Vietnam.
The evaluation was formative in nature and we ensured that key stakeholders were engaged in collaborative and participatory processes of analysis and interpretation. Stakeholders had an opportunity to undergo a structured process of analysis of raw and partially analysed data to ensure that they were part of a process of making meaning out of data and are not simply passive consumers of insights and evidence.
Read ‘Strategic Review 2017‘.
Image © Health Photo Credit: Itad